Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Pantheon International director raises stake

(Sharecast News) - Pantheon International revealed on Thursday that non-executive director John Burgess had acquired 166,038 ordinary shares in the FTSE 250-listed investment trust. Burgess, who made the purchase via his interest in The November 1990 Trust, snapped up the shares at an average price of 324.65p each, for a total value of £539,047.48.

As of 1620 BST, Pantheon shares were flat at 323.50p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Pantheon International (PIN) Director name: Burgess ,John Amount purchased: 166,038 @ 324.65p Value: £539,047.48

Staffline Group (STAF) Director name: Spain,Thomas Amount purchased: 101,266 @ 35.55p Value: £36,000.06

Hydrogen Utopia International (HUI) Director name: White,Howard Amount purchased: 500,000 @ 4.88p Value: £24,400.00

Seed Innovations Limited (SEED) Director name: Jersey,Lance De Amount purchased: 1,000,000 @ 1.45p Value: £14,500.00

Top Director Sells

Bloomsbury Publishing (BMY) Director name: Newton,Nigel Amount sold: 58,378 @ 713.30p Value: £416,410.27

Bloomsbury Publishing (BMY) Director name: Scott-Bayfield,Penny Amount sold: 38,085 @ 713.30p Value: £271,660.30

Staffline Group (STAF) Director name: Spain,Thomas Amount sold: 101,266 @ 35.55p Value: £36,000.06

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 600 @ $4.30 Value: $2,127.48

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 400 @ $4.26 Value: $1,403.48

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 400 @ $4.23 Value: $1,395.23

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 301 @ $4.27 Value: $1,059.84

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 296 @ $4.31 Value: $1,052.00

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 300 @ $4.23 Value: $1,046.43

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 206 @ $4.23 Value: $718.55

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 200 @ $4.35 Value: $717.41

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 152 @ $4.28 Value: $536.46

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 87 @ $4.29 Value: $307.77

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 58 @ $4.26 Value: $203.98

Share this article

Related Sharecast Articles

London midday: Stocks stay down as China retaliates against US tariffs
(Sharecast News) - London stocks were still in the red by midday on Tuesday as investors mulled the impact of the latest developments in the Trump tariff drama, after China announced retaliatory tariffs on a range of US imports.
Europe midday: Shares pare losses as investors digest China tariff move
(Sharecast News) - European stocks pared losses as investors digested China's retaliatory moves against US tariffs and the 30-day pause on levies against Canada and Mexico.
US pre-open: Futures slightly lower as tariff headlines remain in focus
(Sharecast News) - Wall Street futures were in the red ahead of the bell on Tuesday as the effects of the new White House administration's tariffs on a number of its closest trading partners continued to be seen.
Asia report: Markets bounce back from Trump tariff sell-off
(Sharecast News) - Asia-Pacific markets advanced on Tuesday as investor sentiment improved following Donald Trump's decision to pause tariffs on Mexico and Canada for a month.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.